Subscribe to RSS

DOI: 10.1055/a-2651-0612
Emerging Trends in Global Lung Cancer Burden
Funding This work was supported by the Lee and the Ho Families Respiratory Health Research Fund.

Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide, with its burden shaped by evolving risk factors, demographic changes, and healthcare disparities. Over the past decades, while age-standardized incidence and mortality rates have declined, the absolute number of cases has risen due to population growth and aging. Tobacco smoking remains the most common risk factor, accounting for approximately 60% of cases globally, though its contribution has declined in high-income regions due to effective tobacco control. Conversely, countries with lower socioeconomic development, particularly in East and South Asia, face rising incidence and mortality driven by increasing smoking prevalence, air pollution, and limited access to healthcare. Emerging risk factors, such as ambient air pollution and genetic predisposition, are increasingly significant, particularly in regions with lower Human Development Index scores. Sex disparities are evident, with lung cancer rates declining among men in many high-income countries but rising among women globally. Early-onset lung cancer is also an emerging concern, especially in middle socio-demographic index regions, driven by smoking, environmental exposures, and genetic factors. By 2035, it is predicted that lung cancer deaths could reach 3 million annually. To address the impact of the growing lung cancer burden, a multifaceted approach is needed, including strengthened tobacco control, improved air quality, promotion of clean cooking fuels, and expanded low-dose computed tomography screening, particularly in resource-constrained regions.
Keywords
lung cancer - epidemiology - smoking - air pollution - early-onset lung cancer - global cancer trendsPublication History
Article published online:
14 August 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Bray F, Laversanne M, Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (03) 229-263
- 2 Li C, Lei S, Ding L. et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl) 2023; 136 (13) 1583-1590
- 3 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
- 4 Darby S, Hill D, Auvinen A. et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 2005; 330 (7485): 223
- 5 Didkowska J, Wojciechowska U, Mańczuk M, Łobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med 2016; 4 (08) 150
- 6 Jemal A, Miller KD, Ma J. et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med 2018; 378 (21) 1999-2009
- 7 Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 2019; 28 (10) 1563-1579
- 8 Tu Z, Liao S, Chen C. et al. The long-term spatiotemporal trends in lung cancer burden and its risk factors at global, regional, and national levels, 1992-2021: the global burden of disease study 2021. Cancer Commun (Lond) 2024; 44 (12) 1418-1421
- 9 Li W-Z, Gui X, Liang H, Wang W, Liang W, He J. Geographic and sociodemographic variations in disease burden, epidemiological trends, and risk factors of early-onset lung cancer: a global analysis. J Clin Oncol 2024; 42 (16) 11169
- 10 Aldea M, Parisi C, Mogenet A. et al. 1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC). Ann Oncol 2021; 32: S1024-S1025
- 11 Laguna JC, Tagliamento M, Lambertini M, Hiznay J, Mezquita L. Tackling non-small cell lung cancer in young adults: from risk factors and genetic susceptibility to lung cancer profile and outcomes. Am Soc Clin Oncol Educ Book 2024; 44 (03) e432488
- 12 Soerjomataram I, Cabasag C, Bardot A. et al; SURVCAN-3 collaborators. Cancer survival in Africa, Central and South America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol 2023; 24 (01) 22-32
- 13 Guo L, Zhu C, Cai L. et al. Global burden of lung cancer in 2022 and projected burden in 2050. Chin Med J (Engl) 2024; 137 (21) 2577-2582
- 14 Ferrari AJ, Santomauro DF, Aali A. et al; GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021. Lancet 2024; 403 (10440): 2133-2161
- 15 Wéber A, Morgan E, Vignat J. et al. Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040. BMJ Open 2023; 13 (05) e065303
- 16 Roser M. Human Development Index (HDI). Accessed July 10, 2025 at: https://ourworldindata.org/human-development-index
- 17 McGillivray M, Noorbakhsh F. Composite Indexes of Human Well-being: Past, Present and Future. 2007:113–134
- 18 Kassebaum NJ, Arora M, Barber RM. et al; GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet 2016; 388 (10053): 1603-1658
- 19 Cai L, Zhu CX, Zhang XL, Fang Y, Yang HY, Guo LW. [Interpretation of global lung cancer statistics]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45 (04) 585-590
- 20 Jani CT, Kareff SA, Morgenstern-Kaplan D. et al. Evolving trends in lung cancer risk factors in the ten most populous countries: an analysis of data from the 2019 global burden of disease study. EClinicalMedicine 2025; 79: 103033
- 21 Wynder EL, Muscat JE. The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect 1995; 103 (Suppl. 08) 143-148
- 22 Repana D, Spicer J. In: Cham., ed. Epidemiology of Lung Cancer: Springer 2017:pp. 347–366
- 23 Alonso R, Piñeros M, Laversanne M. et al. Lung cancer incidence trends in Uruguay 1990-2014: an age-period-cohort analysis. Cancer Epidemiol 2018; 55: 17-22
- 24 Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl. 08) S4-S66
- 25 Miranda-Filho A, Piñeros M, Bray F. The descriptive epidemiology of lung cancer and tobacco control: a global overview 2018. Salud Publica Mex 2019; 61 (03) 219-229
- 26 Cancer Epidemiology and Prevention: Oxford University Press, 2017
- 27 Jemal A, Schafer EJ, Sung H. et al. The burden of lung cancer in women compared with men in the US. JAMA Oncol 2023; 9 (12) 1727-1728
- 28 World Health Organization (WHO). WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke: executive summary. Accessed July 10, 2025 at: https://www.who.int/publications/i/item/9789240077485
- 29 Ciabattini M, Rizzello E, Lucaroni F, Palombi L, Boffetta P. Systematic review and meta-analysis of recent high-quality studies on exposure to particulate matter and risk of lung cancer. Environ Res 2021; 196: 110440
- 30 Yu P, Guo S, Xu R. et al. Cohort studies of long-term exposure to outdoor particulate matter and risks of cancer: a systematic review and meta-analysis. Innovation (Camb) 2021; 2 (03) 100143
- 31 Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 2023; 20 (09) 624-639
- 32 Fidler-Benaoudia MM, Torre LA, Bray F, Ferlay J, Jemal A. Lung cancer incidence in young women vs. young men: a systematic analysis in 40 countries. Int J Cancer 2020; 147 (03) 811-819
- 33 Kurmi OP, Arya PH, Lam KB, Sorahan T, Ayres JG. Lung cancer risk and solid fuel smoke exposure: a systematic review and meta-analysis. Eur Respir J 2012; 40 (05) 1228-1237
- 34 McClintock TR, Chen Y, Bundschuh J. et al. Arsenic exposure in Latin America: biomarkers, risk assessments and related health effects. Sci Total Environ 2012; 429: 76-91
- 35 Grosche B, Kreuzer M, Kreisheimer M, Schnelzer M, Tschense A. Lung cancer risk among German male uranium miners: a cohort study, 1946-1998. Br J Cancer 2006; 95 (09) 1280-1287
- 36 Krewski D, Lubin JH, Zielinski JM. et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 2005; 16 (02) 137-145
- 37 Safari A, Mortazavi SA, Ghadimi-Moghadam A, Haghani M, Mortazavi SMJ, Sihver L. Exploring the disparity in indoor/outdoor time and radon exposure as possible factors contributing to the unexpected increase in lung cancer risk among non-smoking women. J Biomed Phys Eng 2024; 14 (04) 415-420
- 38 Wang C, Chang Y, Ren J. et al. Modifiable risk-attributable and age-related burden of lung cancer in China, 1990-2019. Cancer 2023; 129 (18) 2871-2886
- 39 Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med 2019; 25 (01) 44-56
- 40 Ji X, Chen J, Ye J, Xu S, Lin B, Hou K. Epidemiological analysis of global and regional lung cancer mortality: based on 30-year data analysis of global burden disease database. Healthcare (Basel) 2023; 11 (22) 2920
- 41 Ragavan M, Patel MI. The evolving landscape of sex-based differences in lung cancer: a distinct disease in women. Eur Respir Rev 2022; 31 (163) 210100
- 42 Li W-Z, Liang H, Liu J. et al. Patterns and trends in incidence, survival, and treatment among patients with early-onset lung cancer in the U.S.: a population-based study. J Clin Oncol 2024; 42 (16) e22517
- 43 Levi F, Bosetti C, Fernandez E. et al. Trends in lung cancer among young European women: the rising epidemic in France and Spain. Int J Cancer 2007; 121 (02) 462-465
- 44 Hsu CH, Tseng CH, Chiang CJ. et al. Characteristics of young lung cancer: analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget 2016; 7 (29) 46628-46635
- 45 Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol 2016; 2 (03) 313-320
- 46 Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V. et al. Comparison of clinical and genetic characteristics between younger and older lung cancer patients. Arch Bronconeumol 2024; 60 (02) 88-94
- 47 Yang S, Song Z, Cheng G. Genomic alterations and survival in young patients aged under 40 years with completely resected non-small cell lung cancer. Ann Transl Med 2019; 7 (07) 140
- 48 Wang Y, Chen J, Ding W, Yan B, Gao Q, Zhou J. Clinical features and gene mutations of lung cancer patients 30 years of age or younger. PLoS One 2015; 10 (09) e0136659
- 49 Fu Y, Liu J, Chen Y, Liu Z, Xia H, Xu H. Gender disparities in lung cancer incidence in the United States during 2001-2019. Sci Rep 2023; 13 (01) 12581
- 50 Kang J, Kim T, Han KD. et al. Risk factors for early-onset lung cancer in Korea: analysis of a nationally representative population-based cohort. Epidemiol Health 2023; 45: e2023101
- 51 Kreuzer M, Kreienbrock L, Gerken M. et al. Risk factors for lung cancer in young adults. Am J Epidemiol 1998; 147 (11) 1028-1037
- 52 Asomaning K, Miller DP, Liu G. et al. Second hand smoke, age of exposure and lung cancer risk. Lung Cancer 2008; 61 (01) 13-20
- 53 Betser L, Glorion M, Mordant P. et al. Cannabis use and lung cancer: time to stop overlooking the problem?. Eur Respir J 2021; 57 (05) 2004132
- 54 Hughes DJ, Kapiris M, Podvez Nevajda A. et al. Non-small cell lung cancer (NSCLC) in young adults, Age < 50, is associated with late stage at presentation and a very poor prognosis in patients that do not have a targeted therapy option: a real-world study. Cancers (Basel) 2022; 14 (24) 6056
- 55 Oxnard GR, Chen R, Pharr JC. et al. Germline EGFR mutations and familial lung cancer. J Clin Oncol 2023; 41 (34) 5274-5284
- 56 Mukherjee S, Bandlamudi C, Hellmann MD. et al. Germline pathogenic variants impact clinicopathology of advanced lung cancer. Cancer Epidemiol Biomarkers Prev 2022; 31 (07) 1450-1459
- 57 Wei B, Zhao J, Li J. et al. Pathogenic germline variants in BRCA1 and TP53 increase lung cancer risk in Chinese. Cancer Med 2023; 12 (23) 21219-21228
- 58 Garcia M, Garcia de Herreros M, Auclin E. et al. OA13.04 prevalence of molecular alterations in NSCLC and estimated indoor radon in Europe: Radon Europe Study. J Thorac Oncol 2022; 17 (9, suppl): S34-S35
- 59 Ge C, Peters S, Olsson A. et al. Respirable crystalline silica exposure, smoking, and lung cancer subtype risks. A pooled analysis of case-control studies. Am J Respir Crit Care Med 2020; 202 (03) 412-421
- 60 Villeneuve PJ, Parent MÉ, Harris SA, Johnson KC. Canadian Cancer Registries Epidemiology Research Group. Occupational exposure to asbestos and lung cancer in men: evidence from a population-based case-control study in eight Canadian provinces. BMC Cancer 2012; 12: 595
- 61 2023 Global Progress Report on Implementation of the WHO Framework Convention on Tobacco Control. Accessed July 10, 2025 at: https://fctc.who.int/resources/publications/m/item/2023-global-progress-report
- 62 de Koning HJ, van der Aalst CM, de Jong PA. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382 (06) 503-513
- 63 Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol 2019; 14 (10) 1732-1742
- 64 Patz Jr EF, Pinsky P, Gatsonis C. et al; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174 (02) 269-274
- 65 American Cancer Society. Lung Cancer Screening Guidelines. American Cancer Society. Accessed July 10, 2025 at: https://www.cancer.org/health-care-professionals/american-cancer-society-prevention-early-detection-guidelines/lung-cancer-screening-guidelines.html
- 66 Cancer Australia. Lung Cancer Screening. Cancer Australia, Australian Government. Accessed July 10, 2025 at: https://www.canceraustralia.gov.au/key-initiatives/national-lung-cancer-screening-program
- 67 Van Meerbeeck JP, O'Dowd E, Ward B, Van Schil P, Snoeckx A. Lung cancer screening: new perspective and challenges in Europe. Cancers (Basel) 2022; 14 (09) 2343
- 68 Ward B, Koziar Vašáková M, Robalo Cordeiro C. et al. Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union's new recommendations on lung cancer screening. ERJ Open Res 2023; 9 (03) 00026-2023
- 69 Chang GC, Chiu CH, Yu CJ. et al; TALENT Investigators. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. Lancet Respir Med 2024; 12 (02) 141-152